vs
Side-by-side financial comparison of Intellia Therapeutics, Inc. (NTLA) and ATRenew Inc. (RERE). Click either name above to swap in a different company.
ATRenew Inc. is the larger business by last-quarter revenue ($43.2M vs $23.0M, roughly 1.9× Intellia Therapeutics, Inc.). ATRenew Inc. runs the higher net margin — 16.9% vs -416.2%, a 433.1% gap on every dollar of revenue.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
ATRenew Inc.REREEarnings & Financial Report
ATRenew Inc. operates a leading pre-owned consumer electronics transaction and servicing ecosystem primarily in China. Its core services include end-to-end device recycling, professional quality inspection, certified refurbishment, and resale of smartphones, laptops, tablets and other digital products, serving both individual consumers and enterprise clients across domestic and select Southeast Asian markets.
NTLA vs RERE — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2023
| Metric | | |
|---|---|---|
| Revenue | $23.0M | $43.2M |
| Net Profit | $-95.8M | $7.3M |
| Gross Margin | — | — |
| Operating Margin | -428.9% | — |
| Net Margin | -416.2% | 16.9% |
| Revenue YoY | 78.8% | — |
| Net Profit YoY | 25.7% | — |
| EPS (diluted) | $-0.81 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.0M | — | ||
| Q3 25 | $13.8M | — | ||
| Q2 25 | $14.2M | — | ||
| Q1 25 | $16.6M | — | ||
| Q4 24 | $12.9M | — | ||
| Q3 24 | $9.1M | — | ||
| Q2 24 | $7.0M | — | ||
| Q1 24 | $28.9M | — |
| Q4 25 | $-95.8M | — | ||
| Q3 25 | $-101.3M | — | ||
| Q2 25 | $-101.3M | — | ||
| Q1 25 | $-114.3M | — | ||
| Q4 24 | $-128.9M | — | ||
| Q3 24 | $-135.7M | — | ||
| Q2 24 | $-147.0M | — | ||
| Q1 24 | $-107.4M | — |
| Q4 25 | -428.9% | — | ||
| Q3 25 | -808.9% | — | ||
| Q2 25 | -772.2% | — | ||
| Q1 25 | -726.6% | — | ||
| Q4 24 | -1059.9% | — | ||
| Q3 24 | -1589.0% | — | ||
| Q2 24 | -1998.6% | — | ||
| Q1 24 | -394.0% | — |
| Q4 25 | -416.2% | — | ||
| Q3 25 | -735.2% | — | ||
| Q2 25 | -710.8% | — | ||
| Q1 25 | -687.6% | — | ||
| Q4 24 | -1001.2% | — | ||
| Q3 24 | -1489.5% | — | ||
| Q2 24 | -2112.6% | — | ||
| Q1 24 | -371.3% | — |
| Q4 25 | $-0.81 | — | ||
| Q3 25 | $-0.92 | — | ||
| Q2 25 | $-0.98 | — | ||
| Q1 25 | $-1.10 | — | ||
| Q4 24 | $-1.27 | — | ||
| Q3 24 | $-1.34 | — | ||
| Q2 24 | $-1.52 | — | ||
| Q1 24 | $-1.12 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $449.9M | $228.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $671.4M | $557.1M |
| Total Assets | $842.1M | $722.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $449.9M | — | ||
| Q3 25 | $511.0M | — | ||
| Q2 25 | $459.7M | — | ||
| Q1 25 | $503.7M | — | ||
| Q4 24 | $601.5M | — | ||
| Q3 24 | $658.1M | — | ||
| Q2 24 | $691.1M | — | ||
| Q1 24 | $791.3M | — |
| Q4 25 | $671.4M | — | ||
| Q3 25 | $748.4M | — | ||
| Q2 25 | $715.3M | — | ||
| Q1 25 | $779.9M | — | ||
| Q4 24 | $872.0M | — | ||
| Q3 24 | $962.6M | — | ||
| Q2 24 | $971.1M | — | ||
| Q1 24 | $1.0B | — |
| Q4 25 | $842.1M | — | ||
| Q3 25 | $925.3M | — | ||
| Q2 25 | $898.9M | — | ||
| Q1 25 | $986.2M | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.3B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-69.3M | — |
| Free Cash FlowOCF − Capex | $-69.4M | — |
| FCF MarginFCF / Revenue | -301.6% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-395.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-69.3M | — | ||
| Q3 25 | $-76.9M | — | ||
| Q2 25 | $-99.6M | — | ||
| Q1 25 | $-148.9M | — | ||
| Q4 24 | $-85.2M | — | ||
| Q3 24 | $-84.8M | — | ||
| Q2 24 | $-58.2M | — | ||
| Q1 24 | $-120.7M | — |
| Q4 25 | $-69.4M | — | ||
| Q3 25 | $-76.9M | — | ||
| Q2 25 | $-99.9M | — | ||
| Q1 25 | $-149.7M | — | ||
| Q4 24 | $-86.2M | — | ||
| Q3 24 | $-86.1M | — | ||
| Q2 24 | $-59.2M | — | ||
| Q1 24 | $-123.2M | — |
| Q4 25 | -301.6% | — | ||
| Q3 25 | -558.2% | — | ||
| Q2 25 | -701.0% | — | ||
| Q1 25 | -900.1% | — | ||
| Q4 24 | -669.4% | — | ||
| Q3 24 | -945.2% | — | ||
| Q2 24 | -850.9% | — | ||
| Q1 24 | -425.7% | — |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 7.6% | — | ||
| Q3 24 | 14.0% | — | ||
| Q2 24 | 14.5% | — | ||
| Q1 24 | 8.7% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
RERE
Segment breakdown not available.
